Made Scientific Acquires Resilience’s 85K-Square-Foot Cell Therapy Facility
The operational site and its team have completed 145 batches under good manufacturing practice standards, enabling immediate client onboarding.
Key Points
- Made Scientific acquired an operational 85,000-square-foot cell therapy manufacturing facility in East Norriton, Pennsylvania.
- The facility and its manufacturing team have completed 145 GMP batches across autologous and allogeneic programs.
- The acquisition expands Made Scientific’s U.S. East Coast footprint to approximately 145,000 square feet with 15 qualified GMP manufacturing suites.
Made Scientific acquired an 85,000-square-foot clinical-to-commercial cell therapy manufacturing facility in East Norriton, Pennsylvania, from National Resilience. The transaction closed on September 18, 2026.
The facility was operational at closing, allowing Made Scientific to begin onboarding client programs without the ramp-up and qualification timelines associated with a new facility. The site and its manufacturing team have completed 145 GMP batches across autologous (sourced from the patient) and allogeneic (donor derived) programs, including CAR-T and B-cell therapies.
The East Norriton acquisition adds clinical-to-commercial GMP capacity to Made Scientific’s East Coast manufacturing network. It also provides sponsors with multiple regional facility options as programs advance through clinical development and toward commercial manufacturing.
Manufacturing and Expansion Capacity
The East Norriton facility is designed for high-throughput, end-to-end cell therapy manufacturing. Its existing infrastructure includes:
- Eight Grade B/C cleanrooms
- One Grade C ballroom
- One Grade B fill-finish suite
- On-site quality control and analytical testing laboratories
- High-bay warehousing
- 30,000 square feet of expansion space
The expansion area has a design and engineering plan supporting eight additional ballrooms for future growth and client-specific builds. The facility supports starting material, drug substance and drug product manufacturing through custom and platform technology transfers.
Made Scientific plans to equip the site with scalable 3D bioreactor platforms of up to 200 liters, advanced cell-harvest equipment, automated fill-finish systems and lyophilization capacity.
The additional capacity will support programs involving mesenchymal stem cells (MSCs), secretomes, exosomes and senolytic therapies. It will also complement immune-cell, induced pluripotent stem cell (iPSC)-derived and engineered-tissue programs supported at the company’s Princeton facility. Clients may transfer existing processes to East Norriton or use Made Scientific’s ReadyMADE™ platforms across multiple modalities.
“The acquisition of an operational facility with an experienced manufacturing team represents a significant advance in our ability to support clients from clinical to commercial,” said Syed T. Husain, Chairman and CEO of Made Scientific. “Sponsors advancing therapies toward approval require manufacturing capacity that is available when their programs reach it. East Norriton provides that capacity today, supported by a demonstrated GMP operating history, and enables us to onboard client programs immediately rather than at the conclusion of a multi-year build. It is also the next step in a manufacturing network we are building deliberately and for the long term, with a strategic shareholder that has backed Made Scientific since 2022.”
Expanded East Coast Network
Made Scientific now operates approximately 145,000 square feet across its U.S. East Coast network. The combined infrastructure includes 15 qualified GMP manufacturing suites, process and analytical development laboratories, and quality control testing at both locations.
The company is preparing its Princeton facility for an FDA pre-licensure inspection in early 2027, with the East Norriton facility expected to follow.
The acquisition comes as the cell therapy contract development and manufacturing organization sector consolidates and some capacity leaves the market while additional therapies advance into late-stage trials and regulatory review.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
